Mechanistically, we demonstrate that c-Myc-mediated compensatory metabolic changes inhibit response to metformin and that the anti-cancer effects of metformin can be restored through the addition of either a glycolytic or c-Myc inhibitor. Here, MYC is linked to cancer.